Cancer Treatment Updates
Three-Drug Combination Benefits Some Patients with Relapsed Multiple Myeloma
January 8th, 2015
Interim results from an international, randomized phase III trial suggest that adding carfilzomib (Kyprolis®) to a standard treatment improves outcomes for patients with multiple myeloma whose cancer has relapsed. Participants in the study who received carfilzomib plus lenalidomide (Revlimid®) and dexamethasone lived a median of 8.7 months longer without the disease getting worse than patients who received lenalidomide and dexamethasone alone.Three-Drug Combination Benefits Some Patients with Relapsed Multiple Myeloma
January 8th, 2015
Interim results from an international, randomized phase III trial suggest that adding carfilzomib (Kyprolis®) to a standard treatment improves outcomes for patients with multiple myeloma whose cancer has relapsed. Participants in the study who received carfilzomib plus lenalidomide (Revlimid®) and dexamethasone lived a median of 8.7 months longer without the disease getting worse than patients who received lenalidomide and dexamethasone alone.Combining Two Types of Targeted Therapy Improves Survival in Some Patients with Advanced Melanoma (Updated)
January 5th, 2015
In two phase III trials, patients with metastatic melanoma whose tumors have specific mutations in the BRAF gene lived longer following treatment with dabrafenib (Tafinlar®), a BRAF inhibitor, plus trametinib (Mekinist®), a MEK inhibitor, than following treatment with a BRAF inhibitor alone.Nivolumab Improves Overall Survival in Patients with Metastatic Melanoma without a BRAF Mutation
January 5th, 2015
Results from an international phase III trial show that nivolumab (Opdivo®) improves overall survival compared with the chemotherapy drug dacarbazine in patients with metastatic melanoma whose tumors do not have a mutation in the BRAF gene.Combining Two Types of Targeted Therapy Improves Survival in Some Patients with Advanced Melanoma
January 5th, 2015
In two phase III trials, patients with metastatic melanoma whose tumors have specific mutations in the BRAF gene lived longer following treatment with dabrafenib (Tafinlar®), a BRAF inhibitor, plus trametinib (Mekinist®), a MEK inhibitor, than following treatment with a BRAF inhibitor alone.Nivolumab Improves Overall Survival in Patients with Metastatic Melanoma without a BRAF Mutation
January 5th, 2015
Results from an international phase III trial show that nivolumab (Opdivo®) improves overall survival compared with the chemotherapy drug dacarbazine in patients with metastatic melanoma whose tumors do not have a mutation in the BRAF gene.Combining Two Types of Targeted Therapy Improves Survival in Some Patients with Advanced Melanoma
January 5th, 2015
In two phase III trials, patients with metastatic melanoma whose tumors have specific mutations in the BRAF gene lived longer following treatment with dabrafenib (Tafinlar®), a BRAF inhibitor, plus trametinib (Mekinist®), a MEK inhibitor, than following treatment with a BRAF inhibitor alone.Nivolumab Improves Overall Survival in Patients with Metastatic Melanoma without a BRAF Mutation
January 5th, 2015
Results from an international phase III trial show that nivolumab (Opdivo®) improves overall survival compared with the chemotherapy drug dacarbazine in patients with metastatic melanoma whose tumors do not have a mutation in the BRAF gene.Rituximab Retreatment after Disease Progression Is Comparable to Rituximab Maintenance Therapy in Patients with Low-Tumor Burden Follicular Lymphoma
October 1st, 2014
In a randomized clinical trial, patients with low–tumor burden follicular lymphoma whose cancer responded to initial treatment with rituximab (Rituxan®) experienced similar disease control regardless of whether they subsequently received maintenance therapy with rituximab or were retreated with rituximab only when there was evidence of disease progression.Rituximab Retreatment after Disease Progression Is Comparable to Rituximab Maintenance Therapy in Patients with Low-Tumor Burden Follicular Lymphoma
October 1st, 2014
In a randomized clinical trial, patients with low–tumor burden follicular lymphoma whose cancer responded to initial treatment with rituximab (Rituxan®) experienced similar disease control regardless of whether they subsequently received maintenance therapy with rituximab or were retreated with rituximab only when there was evidence of disease progression.